← Back to Search

Magnetic Tracer

indocyanine green (ICG) for Colorectal Cancer

Phase 1 & 2
Waitlist Available
Led By Matthew Tillman
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights


This trial is testing a new way to map the sentinel lymph node (SLN) using magnetic tracers and indocyanine green (ICG) in patients with colorectal cancer. They are also testing the safety of colonoscopic peritumoral injection of magnetic nanoparticles and ICG.

Eligible Conditions
  • Colorectal Cancer


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the feasibility how the Sentinel Lymph Node (SLN) mapping by using novel magnetic tracers (FerroTrace) and using the indocyanine green (ICG) for colorectal cancer.

Trial Design

1Treatment groups
Experimental Treatment
Group I: FerroTraceTM (magnetic tracer)Experimental Treatment2 Interventions
a special type of fluorescent dye called indocyanine green (ICG) during surgery can help surgeons find the lymph nodes that the cancer is most likely to have spread to in colorectal cancer patients.
First Studied
Drug Approval Stage
How many patients have taken this drug
indocyanine green (ICG)
Completed Phase 3

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,002 Previous Clinical Trials
1,794,279 Total Patients Enrolled
Matthew TillmanPrincipal InvestigatorM.D. Anderson Cancer Center
George ChangPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
120 Total Patients Enrolled
~0 spots leftby Jul 2025